The Diary Of A CEO with Steven Bartlett
Also in Business
Science
BioCentury This Week
by BioCentury
Today: #184 in Science on our combined chart.
Chart positions today
Where it charts
Today’s combined position on our country charts, alongside the US charts above.
If you like BioCentury This Week, try…
Financial Audit
Also in Business
Huberman Lab
Also in Life Sciences
StarTalk with Neil deGrasse Tyson
Also in Science
The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes
Similar topics: biotech and biopharma
Biotech Hangout
Also in Life Sciences
Ranking history
Position on the Science combined chart over the last 30 days. Toggle platforms to compare their positions. Lower rank numbers are better; #1 is at the top.
View as table
| Date | Combined Rank | Apple Podcasts |
|---|---|---|
| Oct 7 | #184 | #167 |
| Oct 6 | — | #191 |
About the show
BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
Latest episodes
-
Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners
October 6, 2026 · 30 minPharma partnering in China is getting earlier and broader, with Merck & Co., Novo Nordisk and Novartis striking multibillion-dollar deals for assets spanning new modalities and disease areas. On the latest BioCentury This Week podcast…
-
Ep. 390 - Live from Amsterdam: Grand Rounds Europe takeaways
September 30, 2026 · 34 minMechanisms broad enough to matter across many diseases, from mitochondrial health to the biology of aging, emerged as a defining theme at Grand Rounds Europe in Amsterdam. On a special live edition of the BioCentury This Week podcast…
-
Ep. 389 - IgA nephropathy, Overton hearing, reverse mergers' new look
September 29, 2026 · 37 minSeven global approvals in five years, validated biomarkers and FDA flexibility have turned IgA nephropathy from a neglected rare disease into a crowded field, with Biogen, Novartis, Takeda, Climb Bio and Jade chasing targets such as APRIL…
-
Ep. 388 - Biotech IPOs, CAR T safety & pharma tariffs
September 22, 2026 · 32 minThe first biotech IPO in a month, Electra's upsized $350 million offering, fell in its trading debut, testing investor appetite while a wave of reverse mergers showcases an alternate route to NASDAQ. On the latest BioCentury This Week…
-
Ep. 387 - Psychedelics at FDA, Mike Davis’ CDER & tRNAs
September 15, 2026 · 31 minNote: This episode was briefly published with an incorrect audio file, which has since been corrected. FDA is prepared to approve psychedelic therapies for chronic psychiatric disorders before sponsors have fully determined how long the…
-
Ep. 386 - Novartis misses, pharma deals analysis, MFN carve-outs
September 9, 2026 · 35 minA pair of high profile clinical setbacks has wiped out more than $40 billion in market cap for Novartis, most of which stemmed from the Phase III miss of antisense oligonucleotide therapy pelacarsen. On the latest BioCentury This Week…
-
Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton
September 1, 2026 · 36 minMid-sized biopharma companies are under growing pressure to accept most-favored nation drug pricing deals with the White House. On the latest BioCentury This Week podcast, BioCentury's analysts assess the trade-offs companies face, the…
-
Ep. 384 - Back to School Special: The global FIH trials race
August 28, 2026 · 43 minChina has changed the global narrative on delivering early human clinical data, with a new bar for speed and efficiency. And now drug developers and policymakers around the world have gotten the message and know that this is no time for…